Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

two-drug regime

Bristol-Myers Squibb (BMS) building

BMS files fixed-dose HIV combination in US

Combines Reyataz with Gilead Sciences' cobicistat

EU flag

European Commission sets out HIV/Aids action plan

Says two-year programme proves HIV/Aids remains an EU health policy priority

Bristol-Myers Squibb (BMS) building

BMS’ novel HIV drug clears phase II trial

Entry inhibitor BMS-660368 moves closer to first-in-class approval

- PMLiVE

A new option for people with HIV

ViiV Healthcare's dolutegravir could capture a significant share of the HIV market and may have blockbuster potential

- PMLiVE

Mylan to sell Gilead’s medicines in India

Includes HIV treatments Viread, Truvada and Stribild

- PMLiVE

ViiV wins European approval for Tivicay

HIV treatment licensed in combination with other anti-retroviral drugs

- PMLiVE

FDA clears Isentress formulation for infants with HIV

Merck's integrase inhibitor available for children as young as four weeks

- PMLiVE

Technology-enhanced HIV testing service triumphs

Dean Street at Home initiative wins PMEA's digital/social award

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

- PMLiVE

J&J files HIV combination in Europe

Seeks approval for fixed-dose tablet containing Prezista and Gilead’s cobicistat

- PMLiVE

EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

Nine new branded medicines recommended for use in Europe

- PMLiVE

ViiV gets US nod for HIV drug dolutegravir

GSK and Pfizer joint venture on course for first drug launch

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links